# Position Review: Sanofi (SAN.PA)

**Date:** 2026-02-03
**Type:** Framework v2.0 Re-Evaluation
**Reviewer:** Claude (Review Agent)

---

## Review Summary

| Metric | Original (v1.0) | v2.0 Updated | Change |
|--------|-----------------|--------------|--------|
| Fair Value Base | EUR 102 | EUR 122 | +19.6% |
| Fair Value Bear | EUR 80 | EUR 98 | +22.5% |
| Fair Value Bull | EUR 133 | EUR 168 | +26.3% |
| MoS at Entry | 19-23% | 35% | Higher |
| MoS Current | 18-22% | 34% | Higher |
| Value Trap Check | Not done | 0/10 PASS | Added |

---

## Key Changes from v1.0 to v2.0

### 1. Business Analysis Framework Added
- Explicit "Why Is It Cheap?" section with contra-thesis
- Value trap checklist (0/10 factors = PASS)
- Informational advantage documented

### 2. Projection Framework with WACC Derivation
```
Original: WACC = 8% (assumed)
v2.0: WACC = 5.63% (derived) â†’ Applied 8% (floor per rules)

Derivation:
- Rf = 2.4% (EUR 10Y)
- Beta = 0.65 (pharma typical)
- ERP = 5.5%
- Ke = 5.98%
- Kd = 3.0% after-tax
- Weights: 88.5% equity, 11.5% debt
```

### 3. Multi-Method Valuation
Original relied heavily on P/E multiples with DCF as "sanity check."

v2.0 uses:
- DCF (40% weight): EUR 92-174 range
- DDM (60% weight): EUR 102-165 range
- Combined: EUR 98-168 range

Higher DDM weight because Sanofi is dividend aristocrat (26 years).

### 4. Macro Fit Section Added
- Verified against world/current_view.md
- Pharma neutral sentiment
- Not directly affected by Korea tariffs
- Demographics favorable

---

## Conclusion

**STATUS: MAINTAIN POSITION**

**Rationale:**
1. v2.0 Fair Value is HIGHER than original (EUR 122 vs EUR 102)
2. Value trap checklist PASSED (0/10 factors)
3. MoS improved from ~22% to 34%
4. All thesis elements remain intact
5. Macro fit is neutral-positive

**Action Required:** None. Position remains attractive.

**Next Review:** After Q1 2026 earnings or kill trigger event.

---

## Profit-Taking Triggers (Updated)

| Price | % of FV | Action |
|-------|---------|--------|
| EUR 97-98 | 80% | Sell 25% |
| EUR 122 | 100% | Sell 50% |
| EUR 168 | Bull | Sell rest |

---

*Review completed 2026-02-03.*
